Integrated GPCR Drug Discovery: A Structured Framework for Modern Programs
- Dr. GPCR News
- 8 hours ago
- 3 min read
Discovery programs rarely fail because of one experiment. They stall when chemistry, modeling, and pharmacology drift apart.
This week, we focus on integration — how to align scientific disciplines before costly translational decisions are made.
Breakthroughs this week: 12th Adhesion GPCR Workshop (Düsseldorf, Sept 16–18, 2026); Free fatty acid receptor 2 allosterism is defined by cellular context; Conformational biosensors delineate endosomal G protein regulation by GPCRs.
Dr. GPCR University Masterclass — Integrated GPCR Discovery in Practice
Dr. GPCR University has been reorganized into a structured, navigable learning framework — and ten reformatted masterclasses are now live in this new architecture.
These sessions span foundational pharmacology, receptor biology, modeling, translational strategy, and advanced GPCR decision logic. Each has been redesigned to function as part of a connected curriculum — not isolated content.
All masterclasses — past and upcoming — are included with Premium Membership.
New courses are delivered live, giving members the opportunity to ask questions directly to the instructors. Recordings are then made available inside the University library for continued access.
Why this matters:
Live engagement plus permanent access. Ask your questions in real time — then revisit the material anytime.
Structured continuity. Move through a cohesive GPCR discovery framework, not disconnected lectures.
Growing depth. As new masterclasses launch, your access expands automatically.
On March 12, the University returns live with a half-day session focused on integrated GPCR discovery across purinergic programs.
Full details will be released soon.
Faculty and their immediate teams receive one year of complimentary Premium Membership.
Eurofins DiscoverX Partnership — Tools and Insight for GPCR Drug Discovery
Modern GPCR discovery depends on more than hypotheses. It depends on infrastructure.
We are thrilled to have entered a strategic partnership with Eurofins DiscoverX, a global provider of GPCR assay platforms and translational biology services covering more than 90% of the human GPCRome.
Their capabilities span cAMP, β-arrestin recruitment, receptor internalization, calcium flux, ligand binding, and integrated discovery support — systems trusted across pharma, biotech, and regulatory programs.
This partnership connects advanced assay and biology capabilities with the scientists and organizations positioned to use them — strengthening the bridge between platform expertise and program execution.
Why this deserves attention:
Assay breadth matters. Platform selection shapes interpretation.
Infrastructure influences velocity. Scalable systems reduce downstream friction.
Field alignment matters. Industry-grade tools signal maturation of GPCR drug discovery.
Dr. GPCR Podcast — Lipid Rafts, Bitter Taste Receptors, and Context-Dependent Signaling
In this episode of the DrGPCR Podcast, Keyvan Sedaghat joins the conversation to explore how membrane compartmentalization shapes GPCR signaling.
From dopamine D1 receptor desensitization and GRK isoform specificity to lipid raft biology, the discussion highlights how membrane context reshapes receptor behavior.
The episode also explores the open-access 7TMR-Raft database cataloguing GPCR–lipid raft associations and the expanding therapeutic landscape of extra-oral bitter taste receptors, including oncology implications.
A recurring theme emerges: computational prediction is powerful — but wet-lab validation remains essential. As AlphaFold and molecular dynamics simulations accelerate hypothesis generation, disciplined experimental confirmation becomes even more critical.
Why this matters:
Membrane context changes signaling outcomes.
Bitter taste receptors extend beyond taste biology.
Prediction without validation creates risk.
Why Dr. GPCR Premium Membership Gives You an Edge
GPCR drug discovery is accelerating — across obesity, CNS, oncology, inflammation, and metabolic disease. Data volume is rising. Platform complexity is expanding. Interpretation risk is increasing.
Dr. GPCR operates as a membership-based, nonprofit initiative — built to strengthen the GPCR field through structured access, curated intelligence, and connected expertise.
Premium Membership unlocks:
Masterclass — Live and on-demand expert-led sessions, fully integrated into Premium.
Weekly News — Curated industry developments, classified publications, and signal-focused intelligence.
Job Listings — GPCR-specific career opportunities across academia, biotech, and pharma.
GPCR Events — Priority tracking of conferences and specialized meetings.
Community Access — Ask the Ecosystem, Happy Hour, and visibility across the GPCR network.
Premium Members also receive a 50%+ discount on Terry’s Corner — unlocking advanced pharmacology depth and live AMAs with Dr. Terry Kenakin (for a limited time).
To strengthen equitable participation across the field:
Masterclass instructors and their immediate teams receive complimentary Premium access.
Scientists living and working in developing countries can join for $25 per year — permanently set to ensure equitable global access.
Institutional and team memberships receive discounted rates to support coordinated participation.
This is not a content subscription. It is structured access to a field.
It supports scientists refining expertise. It strengthens teams executing discovery programs. It equips leaders making strategic and capital decisions.
When decisions compound, fragmented information creates drag. Structured access creates momentum.
Premium delivers that — consistently.
Comments